focus -WSS

focus

author：comprehensive 2025-10-01 00:47:59 - browse：71691

Two researchers look at a computer monitor showing a graph and other data — Adobe

Research universities are voicing concerns over some proposed changes to the process for reviewing scientific misconduct allegations, citing worries that new government requirements would hobble their own independent procedures and constitute a huge administrative burden.

Nearly two decades since it last released research misconduct rules, the U.S. Office of Research Integrity (ORI) is ready to update its requirements for ensuring the scientific standards of projects funded by the U.S. Department of Health and Human Services, including the National Institutes of Health.

The proposed changes, published on Oct. 6, include a new formal process that institutions would follow in reviewing allegations, a 30-day deadline for institutions to assess allegations, and provisions that make it harder to quickly dismiss cases that institutions believe to be “honest errors.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： FDA panel to weigh approval of NurOwn, controversial ALS drug

focus

WSS

Biotech stock slump in 2023: awaiting the turnaround

Senators: Long

Maisha Meds is a PBM, but don't call it that

Microbiome research is starting to find links to chronic diseases

There's an unseen cost to disruptive road

High breast density mammograms need follow

focus

focus

focus

Drug repurposing or repositioning? The language matters

High breast density mammograms need follow

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Future doctors need a strong humanities education

State Dept. review finds Biden bears some blame for Afghanistan failures

Experts study whether long Covid risk adds up with each reinfection

Medicare proposal to cover medical devices draws a mixed reaction

Emergency workers more likely to restrain Black patients: study

United colonoscopy coverage change 'may cost lives,' doctors say

Inaction leaves children at risk from dangerous chemotherapy drug

leisure time

What Congress can do to address the rural doctor shortage

Readout LOUD podcast: possible new ALS drug, artificial wombs

Maisha Meds is a PBM, but don't call it that

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

To bolster infectious disease surveillance, genomics powerhouses team up

Medicare bonuses could stop drug shortages under Senate plan

explore

hotspot

focus

leisure time